Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L9 (RPL9) is a component of the large (60S) subunit of the eukaryotic ribosome and is a member of the L6P family of ribosomal proteins[3][4]. It plays a crucial structural role in the ribosome, participating directly in the process of protein synthesis by catalyzing peptide bond formation and stabilizing the correct folding of rRNA[3][1]. Beyond its canonical ribosomal function, RPL9 has extra-ribosomal activities, including acting as an RNA-binding protein (RBP) that regulates exosomal microRNA (miRNA) cargo and can influence cell proliferation, migration, and invasion in certain cancer contexts, such as hepatocellular carcinoma[2]. Mutations or disruptions in RPL9 are associated with specific diseases, notably Diamond-Blackfan anemia—a congenital erythroid aplasia—and potentially with cancer pathogenesis as an oncogene through its exosomal and miRNA regulatory functions[3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L9 (RPL9).